NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free COLL Stock Alerts $32.47 -1.20 (-3.56%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$32.38▼$33.7450-Day Range$31.50▼$40.9152-Week Range$20.83▼$40.95Volume385,065 shsAverage Volume449,882 shsMarket Capitalization$1.06 billionP/E Ratio13.53Dividend YieldN/APrice Target$39.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Collegium Pharmaceutical alerts: Email Address Collegium Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside20.1% Upside$39.00 Price TargetShort InterestBearish21.78% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.17Based on 16 Articles This WeekInsider TradingSelling Shares$936,215 Sold Last QuarterProj. Earnings Growth10.30%From $5.63 to $6.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector374th out of 923 stocksPharmaceutical Preparations Industry172nd out of 425 stocks 2.1 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.Read more about Collegium Pharmaceutical's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.78% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 1.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 1.8 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Collegium Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $936,215.00 in company stock.Percentage Held by InsidersOnly 3.98% of the stock of Collegium Pharmaceutical is held by insiders.Read more about Collegium Pharmaceutical's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 10.30% in the coming year, from $5.63 to $6.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 13.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 13.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 180.13.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Collegium Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Collegium Pharmaceutical Stock (NASDAQ:COLL)Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More COLL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COLL Stock News HeadlinesMay 17 at 12:08 PM | insidertrades.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Garen G. Bohlin Sells 28,985 SharesMay 18 at 5:40 AM | americanbankingnews.comGaren G. Bohlin Sells 28,985 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) StockMay 14, 2024 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call TranscriptMay 13, 2024 | markets.businessinsider.comCollegium Pharmaceutical Enters ASR Agreement To Repurchase $35 Mln Of Common StockMay 13, 2024 | seekingalpha.comCollegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'May 13, 2024 | globenewswire.comCollegium Announces $35 Million Accelerated Share Repurchase ProgramMay 13, 2024 | americanbankingnews.comPiper Sandler Lowers Collegium Pharmaceutical (NASDAQ:COLL) to NeutralMay 13, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Needham & Company LLCMay 12, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down to $37.86May 11, 2024 | uk.finance.yahoo.comCollegium Pharmaceutical Reports First Quarter 2024 EarningsMay 11, 2024 | uk.finance.yahoo.comCollegium Pharmaceutical Reports First Quarter 2024 EarningsMay 11, 2024 | msn.comCollegium downgraded by Piper Sandler over valuationMay 11, 2024 | msn.comNeedham Downgrades Collegium Pharmaceutical (COLL)May 10, 2024 | finanznachrichten.deCollegium Pharmaceutical, Inc.: Collegium Reports First Quarter 2024 Financial ResultsMay 10, 2024 | markets.businessinsider.comDemystifying Collegium Pharmaceutical: Insights From 4 Analyst ReviewsMay 10, 2024 | finance.yahoo.comCollegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay PacketMay 10, 2024 | msn.comCOLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comCollegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 9, 2024 | finance.yahoo.comCollegium Announces CEO TransitionMay 9, 2024 | marketwatch.comCollegium Pharmaceutical CEO Joe Ciaffoni Steps DownMay 9, 2024 | globenewswire.comCollegium Reports First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comWarner Bros. Discover earnings, Fedspeak: What to watchMay 8, 2024 | markets.businessinsider.comCollegium Pharmaceutical earnings: here's what Wall Street expectsMay 8, 2024 | americanbankingnews.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of "Moderate Buy" from AnalystsMay 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT)See More Headlines Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees197Year FoundedN/APrice Target and Rating Average Stock Price Target$39.00 High Stock Price Target$40.00 Low Stock Price Target$37.00 Potential Upside/Downside+20.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$2.40 Trailing P/E Ratio13.53 Forward P/E Ratio5.77 P/E GrowthN/ANet Income$48.15 million Net Margins16.46% Pretax Margin22.92% Return on Equity104.98% Return on Assets18.00% Debt Debt-to-Equity Ratio1.98 Current Ratio1.21 Quick Ratio1.14 Sales & Book Value Annual Sales$566.77 million Price / Sales1.87 Cash Flow$10.28 per share Price / Cash Flow3.16 Book Value$6.79 per share Price / Book4.78Miscellaneous Outstanding Shares32,720,000Free Float31,413,000Market Cap$1.06 billion OptionableOptionable Beta1.06 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 60)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)President, CEO & Director Comp: $1.69MMs. Colleen Tupper (Age 48)Executive VP & CFO Comp: $848.29kMs. Shirley R. Kuhlmann (Age 40)Executive VP, General Counsel, Chief Administrative Officer & Secretary Comp: $842.9kMr. Scott Dreyer (Age 52)Executive VP & Chief Commercial Officer Comp: $746.58kDr. Thomas B. Smith FAAFP (Age 63)M.D., Executive VP & Chief Medical Officer Comp: $692.91kDr. Christopher Shayne James M.D.Vice President of Investor RelationsMr. Bart J. DunnExecutive Vice President of Strategy & Corporate DevelopmentMr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsVerona PharmaNASDAQ:VRNAProthenaNASDAQ:PRTAEnliven TherapeuticsNASDAQ:ELVNAbCellera BiologicsNASDAQ:ABCLIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsComerica BankBought 9,647 shares on 5/17/2024Ownership: 0.077%Janus Henderson Group PLCSold 64,107 shares on 5/16/2024Ownership: 1.722%Caxton Associates LPBought 44,565 shares on 5/16/2024Ownership: 0.136%California State Teachers Retirement SystemSold 4,111 shares on 5/16/2024Ownership: 0.100%Price T Rowe Associates Inc. MDBought 535 shares on 5/15/2024Ownership: 0.089%View All Insider TransactionsView All Institutional Transactions COLL Stock Analysis - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" COLL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in COLL, but not buy additional shares or sell existing shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price target for 2024? 5 brokers have issued twelve-month price targets for Collegium Pharmaceutical's shares. Their COLL share price targets range from $37.00 to $40.00. On average, they expect the company's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 20.1% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2024? Collegium Pharmaceutical's stock was trading at $30.78 at the beginning of the year. Since then, COLL shares have increased by 5.5% and is now trading at $32.47. View the best growth stocks for 2024 here. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company earned $149.75 million during the quarter, compared to analysts' expectations of $147.66 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 104.98% and a net margin of 16.46%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Pharmaceuticals ETF (XPH), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap Health Care ETF (PSCH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and First Trust Small Cap Growth AlphaDEX Fund (FYC). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $582.3 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.13%), Principal Financial Group Inc. (4.75%), Janus Henderson Group PLC (1.72%), LSV Asset Management (1.16%), Hillsdale Investment Management Inc. (0.34%) and Mutual of America Capital Management LLC (0.28%). Insiders that own company stock include Colleen Tupper, Garen G Bohlin, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COLL) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
